NCM · Biotechnology

HIND (HIND) Stock

$2.17 +0.23% NCM: HIND Healthcare

Valuation

MetricValue
Price$2.17
Market Cap$15.23M
P/E Ratio-0.44
P/B Ratio5.94
P/S Ratio8.83
EPS (TTM)$-4.75
52-Week High$18.60
52-Week Low$1.75
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-500.00%
ROA-166.67%
ROCE-100.00%
Gross Margin48.16%
Operating Margin-4.02%
Net Margin-9.85%
Debt/Equity0.00
Current Ratio1.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$14.0M$11.0M$9.0M$8.0M$0
Operating Profit$-58.0M$-27.0M$-15.0M$-8.0M$-3.0M
Net Profit$-63.0M$-46.0M$-11.0M$-7.0M$-10.0M
EPS$-419004.00$-157897.00$-2771.94$-345.74$-4.75
Op Margin-425.6%-240.9%-168.7%-96.5%-859.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$53.0M$11.0M$11.0M$5.0M$6.0M
Total Liabilities$8.0M$8.0M$4.0M$5.0M$3.0M
Cash$23.0M$4.0M$5.0M$1.0M$5.0M
Borrowings$0$0$0$1.0M$0

Latest News

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio Business Wire · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-22.0M$-17.0M$-4.0M$-4.0M
Investing Cash Flow$2.0M$0$0$0$0
Financing Cash Flow$0$2.0M$0$0$0
Net Cash Flow$20.0M$-19.0M$1.0M$-4.0M$5.0M
Free Cash Flow$-16.0M$-22.0M$-17.0M$-4.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-25.81%
Quick Ratio4.27
Interest Coverage—
Return 1Y-80.30%
Return 3Y-99.97%
Return 5Y-100.00%

Ownership

Insiders Held52.88%
Institutions Held1.52%
Institutions Float Held3.23%
Institutional HolderSharesReport Date
Geode Capital Management, LLC25,7932026-03-31
UBS Group AG22,6752026-03-31
Focus Partners Wealth14,6402026-03-31
Vanguard Fiduciary Trust Co12,1952026-03-31
Vanguard Capital Management LLC9,4632026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMPArmata Pharmaceuticals, Inc. $4.64 -0.43% -0.60 $170.34M 0.00%
CCCC $3.52 -0.85% -2.54 $389.20M 0.00%
CDXS $1.47 -2.00% -5.06 $133.62M 0.00%
CGEN $2.27 -4.83% 7.21 $214.16M 0.00%
IMDXInsight Molecular Diagnostics Inc. $4.70 -0.84% -3.13 $151.76M 0.00%

About HIND

HIND is led by CEO Venkateswarlu Nelabhotla, employs 18 people, headquartered in US, publicly traded since 2016.

HIND stock trades at $2.17 with a market capitalization of $15.23M. The stock is valued at a price-to-earnings (P/E) ratio of -0.44, price-to-book of 5.94, price-to-sales of 8.83. Over the past 52 weeks the stock has ranged between $1.75 and $18.60, and currently trades 88.3% below its 52-week high.

On profitability, HIND generates a return on equity (ROE) of -500.00%, return on capital employed of -100.00%, an operating margin of -4.02%, a net profit margin of -9.85%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides